Viruses, including recurring Influenza or Respiratory Syncytial Virus, pose a threat to human health that is escalating with new outbreaks and the emergence of new viruses, such as Ebola and Zika. A current global effort in the fight against viruses consists in the development of host-targeted antivirals as an alternative to traditional direct-acting antivirals, which favor the emergence of resistant viruses. The Grandvaux Lab is focused on understanding the interplay between a virus and the very first infected cells of the host that shapes the outcome of the infection, either spreading or elimination of the virus. The host mechanisms are either used to mount an innate antiviral defense and proinflammatory response or used by the virus for its own benefit. This research is part of the global effort aimed at identifying host mechanisms that could be targeted to develop new antivirals. We pursue several lines of research, but a large part of our effort, is to characterize the role of redox metabolism. We know that Reactive oxygen species (ROS), either exogenous or produced in response to virus infection, are necessary for host defense, but are also responsible for deleterious effects, often related to virus-associated pathogenesis. We use biochemical and proteomics-based approaches to determine how ROS modify the host proteome via protein oxidation.